Ticagrelor No Better Than Clopidogrel In Peripheral Artery Disease
AstraZeneca announces top-line results from EUCLID trial ahead of the AHA. Ticagrelor is no better than clopidogrel in patients who have peripheral artery disease, a large new study will show. On Tuesday morning AstraZeneca announced the top line results of the EUCLID (Examining Use of Ticagrelor in PAD) trial. The full results will be presented...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Larry Husten Tags: MI/ACS People, Places & Events clopidogrel EUCLID peripheral artery disease ticagrelor Source Type: blogs
More News: AstraZeneca | Cardiology | Clopidogrel | Heart | Peripheral Vascular Disease (PVD) | Plavix | Study